Sex M/F n | 63/0 |
Age years | 72.8±8.1 (49–91) |
Height cm | 165.5±6.5 (149.0–178.0) |
Weight kg | 59.6±8.7 (39.3–83.0) |
BMI kg·m−2 | 21.7±2.8 (15.6–27.9) |
Smoking status former/current n | 55/8 |
Smoking history pack-years | 67.6±39.1 (17.4–192) |
Maintenance inhalation therapy |
LABA | 2 (3.2) |
LABA/ICS | 3 (4.8) |
LAMA | 17 (27.0) |
LAMA/LABA | 3 (4.8) |
LAMA/LABA/ICS | 12 (19.0) |
None | 26 (41.2) |
Mucolytics n (%) | 15 (23.8) |
Macrolides n (%) | 3 (4.8) |
mMRC 0/1/2/3/4 n | 25/24/13/1/0 |
CAT points | 11.2±7.4 (0–30) |
Prior exacerbation yes/no n | 17/46 |
FEV1 L | 1.66±0.68 (0.52–3.21) |
FEV1 % pred | 61.4±21.9 (20.0–112.0) |
GOLD stage, I/II/III/IV n | 16/26/14/7 |
GOLD classification, A/B/C/D n | 24/28/6/5 |
FVC L | 3.21±0.85 (1.46–5.66) |
RV/TLC % | 41.5±9.6 (24.6–67.8) |
DLCO mL·min−1mmHg−1 | 12.67±4.63 (4.09–24.93) |
DLCO % pred | 53.0±17.9 (16.8–95.4) |
WBC μL-1 | 6701±1864 (3000–12 800) |
Neutrophils μL-1 | 4145±1487 (1548–10 714) |
Lymphocytes μL-1 | 1864±653 (815–3722) |
Eosinophils μL-1 | 196±115 (0–628) |
Eosinophils % | 3.0±1.5 (0.0–6.1) |
Cre mg·L−1 | 0.90±0.20 (0.58–1.87) |
eGFR mL·min−1·1.73 m−2 | 67.1±15.1 (27.3–100.8) |
CRP mg·L−1 | 0.22±0.40 (0.0–2.5) |
IgA mg·L−1 | 254.3±112.1 (96–713) |
IgG mg·L−1 | 1286.6±267.3 (724–1801) |
IgM mg·L−1 | 75.7±36.4 (17–192) |
CD4+ T-cells % of lymphocytes | 44.46±9.57 (22.98–67.50) |
CD8+ T-cells % of lymphocytes | 17.18±7.97 (3.95–42.55) |
CD138+ plasma cells % of lymphocytes | 0.20±0.26 (0.01–1.20) |
CD19+ B-cells % of lymphocytes | 5.81±3.09 (1.06–17.00) |
CD19+CD27−IgD+ naïve B-cells % of B-cells | 67.33±14.83 (13.20–93.84) |
CD19+CD27+IgD+ nonswitched memory B-cells % of B-cells | 7.87±4.79 (2.46–34.49) |
CD19+CD27+IgD− switched memory B-cells % of B-cells | 21.25±11.90 (3.31–61.93) |
Kappa-FLC mg·L−1 | 13.4±8.9 (0.6–51.5) |
Lambda-FLC mg·L−1 | 17.7±9.6 (0.8–75.3) |
cFLC mg·L−1 | 31.1±14.7 (1.4–89.9) |